Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2023-12-29 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2023-12-29 English
FORM 6-K
Regulatory Filings
2023-12-29 English
Grifols ha alcanzado una Alianza Estratégica y Contrato de Compraventa de Acciones con Haier Group Corporation para la venta de aproximadamente una participación accionarial del 20% en SRAAS.
M&A Activity Classification · 99% confidence The document is very short (962 characters) and explicitly states it is communicating 'INFORMACIÓN PRIVILEGIADA' (Inside Information/Privileged Information) regarding the partial sale of a stake in Shanghai RAAS Blood Products Co., Ltd. It provides a specific financial detail (a capital gain of approximately 250 million euros) resulting from a transaction. This type of immediate, material, non-periodic disclosure, especially when framed as 'Privileged Information' under Spanish market law (Ley 6/2023, article 226), strongly suggests a regulatory disclosure of a significant event. Since it is not a full report (like 10-K or IR), nor a dividend notice (DIV), nor a management change (MANG), the most appropriate category for a specific, material, non-standard regulatory disclosure that doesn't fit other specific types (like M&A or Capital Change) is the general Regulatory Filings category (RNS). While it relates to a transaction, it is an announcement of the financial impact of a transaction already mentioned, fitting best as a general regulatory update.
2023-12-29 Spanish
FORM 6-K
Regulatory Filings
2023-12-19 English
FORM 6-K
Regulatory Filings
2023-12-19 English
El Consejo de Administración aprueba modificar el Reglamento del Consejo. Cambio de Vicesecretario.
Board/Management Information Classification · 99% confidence The document is an official communication from Grifols, S.A. (a Spanish company, indicated by the address and language) filed as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) under Article 227 of the Spanish Securities Market Law. The content details decisions made by the Board of Directors on December 18, 2023, specifically concerning the modification of the Board's internal regulations ('Reglamento del Consejo de Administración') to adapt to the Good Governance Code, and the acceptance of a resignation and appointment of a new Vice Secretary. The annex provides the revised internal regulations for the Board of Directors. This type of filing, which announces significant internal governance changes, board composition changes, and regulatory compliance updates, most closely aligns with Board/Management Information (MANG) or Governance Information (CGR). Since the core of the document is the modification of the internal rules governing the Board's operation and structure, Governance Information (CGR) is the most precise fit, as it deals with internal rules and board structure, even though management changes (MANG) are also mentioned. It is not a standard financial report (10-K, IR, ER) or a proxy statement (DEF 14A/PSI). Given the focus on adapting the internal rules ('Reglamento de Funcionamiento Interno del Consejo de Administración') to a governance code, CGR is selected.
2023-12-19 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.